Smith & Nephew SNATS (SNN) Stock Price, News & Analysis

Company Overview

Smith & Nephew plc is a global medical technology company that develops and sells products used in surgery, orthopaedics and wound care. Its offerings include implants for hip and knee replacement, instruments and devices for sports medicine and ear, nose and throat procedures, and products designed to manage wounds and support tissue repair.

Founded in 1856 in Hull, England, the company began as a pharmacy business before expanding into medical products. It now serves healthcare providers and patients in markets around the world.

Smith & Nephew’s business focuses on orthopaedics, sports medicine and ear, nose and throat care, and advanced wound management. Its products are used in hospitals and other clinical settings for procedures ranging from joint replacement and minimally invasive surgery to wound treatment.

Key Stats

• Today's Range: $30.52 to $31.12
• 50-Day Range: $26.45 to $32.47
• 52-Week Range: $26.12 to $37.09
• Volume: 2.35 million shs
• Average Volume: 1.30 million shs
• Market Capitalization: $12.96 billion
• P/E Ratio: N/A
• Dividend Yield: 1.91%
• Price Target: $31.91
• Consensus Rating: Reduce

Smith & Nephew SNATS Stock Analysis - MarketRank™

Smith & Nephew SNATS scored higher than 45% of companies evaluated by MarketBeat, and ranked 579th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Smith & Nephew SNATS has received a consensus rating of Reduce. The company's average rating score is 1.91, and is based on no strong buy ratings, 1 buy rating, 8 hold ratings, and 2 sell ratings.

Upside/Downside

The consensus price target for Smith & Nephew SNATS is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Smith & Nephew SNATS has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 6.13%

Earnings Growth

Earnings for Smith & Nephew SNATS are expected to grow by 6.13% in the coming year, from $2.12 to $2.25 per share.

Price to Earnings Growth Ratio

Smith & Nephew SNATS has a PEG Ratio of 1.81. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Smith & Nephew SNATS has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.97% of the float of Smith & Nephew SNATS has been sold short.

Short Interest Ratio / Days to Cover

Smith & Nephew SNATS has a short interest ratio ("days to cover") of 3.12, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Smith & Nephew SNATS has recently decreased by 13.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Smith & Nephew SNATS pays a meaningful dividend of 1.83%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Smith & Nephew SNATS does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Smith & Nephew SNATS will have a dividend payout ratio of 26.22% next year. This indicates that Smith & Nephew SNATS will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.32

News Sentiment

Smith & Nephew SNATS has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Smith & Nephew SNATS this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Smith & Nephew SNATS insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.00% of the stock of Smith & Nephew SNATS is held by insiders.

Percentage Held by Institutions

25.64% of the stock of Smith & Nephew SNATS is held by institutions.

Company Calendar

• Record date for 11/6 Dividend: 10/02/2026
• Ex-Dividend for 11/6 Dividend: 10/02/2026
• Dividend Payable: 11/06/2026
• Today: 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:SNN
• CIK: 845982
• Web: www.smith-nephew.com
• Phone: 441923477100
• Fax: 44-20-7930-3353
• Employees: 16,988
• Year Founded: 1856

Price Target and Rating

• Average Price Target for Smith & Nephew SNATS: $31.91
• High Price Target: $33.88
• Low Price Target: $30.00
• Potential Upside/Downside: +3.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 13.76
• P/E Growth: 1.81
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.62
• Current Ratio: 2.14
• Quick Ratio: 1.11

Sales & Book Value

• Annual Sales: $6.16 billion
• Price / Sales: 2.10
• Cash Flow: $3.27 per share
• Price / Cash Flow: 9.47
• Book Value: $12.45 per share
• Price / Book: 2.49

Miscellaneous

• Outstanding Shares: 418,720,000
• Free Float: 414,529,000
• Market Cap: $12.96 billion
• Optionable: Optionable
• Beta: 0.52